PhD in Biology/Biochemistry from Gothenburg University. 50 + publications in peer reviewed journals, several book chapters and patents. Ten years within AstraZeneca R&D in Cardiovascular Diseases, twelve years at Cellartis/Cellectis as VP Regenerative Medicine, responsible for e.g. the major collaboration with Novo Nordisk on development of a human embryonic stem cell derived beta cell treatment for diabetes. Also, responsible for development of human pluripotent stem cell derived cardiomyocytes and hepatocytes. As of February 2014, CEO of VERIGRAFT AB, a pioneering company within tissue engineering and advanced regenerative medicine for use in treatment of cardiovascular, neuronal and other diseases.